Transportation Issues among Patients Receiving Intravitreal Injections at a Retinal Specialist Clinic (BURDEN Study)

Ophthalmol Retina. 2021 Oct;5(10):1052-1053. doi: 10.1016/j.oret.2021.03.004. Epub 2021 Mar 7.

Authors

Kevin R Card¹, Gabriel M Gordon², Rebecca Carron², Mia Winthrop², Nika Bagheri², Dante J Pieramici³

Affiliations

¹ California Retina Consultants and Research Foundation, Santa Barbara, California; University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii.
² California Retina Consultants and Research Foundation, Santa Barbara, California.
³ California Retina Consultants and Research Foundation, Santa Barbara, California. Electronic address: [email protected].

PMID: 33691181
DOI: 10.1016/j.oret.2021.03.004

No abstract available

MeSH terms

Adult
Aged
Aged, 80 and over
Ambulatory Care Facilities / statistics & numerical data*
Angiogenesis Inhibitors / administration & dosage*
Appointments and Schedules
Female
Health Care Surveys
Health Services Accessibility / statistics & numerical data*
Humans
Intravitreal Injections
Male
Middle Aged
Retinal Diseases / drug therapy
Surveys and Questionnaires
Transportation of Patients / statistics & numerical data*
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Visual Acuity

Substances

Angiogenesis Inhibitors
VEGFA protein, human
Vascular Endothelial Growth Factor A